The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

BACKGROUND: The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated receptors in t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiovasc Diabetol
Hauptverfasser: Leonard, Charles E., Brensinger, Colleen M., Dawwas, Ghadeer K., Deo, Rajat, Bilker, Warren B., Soprano, Samantha E., Dhopeshwarkar, Neil, Flory, James H., Bloomgarden, Zachary T., Gagne, Joshua J., Aquilante, Christina L., Kimmel, Stephen E., Hennessy, Sean
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Original Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7041286/
https://ncbi.nlm.nih.gov/pubmed/32098624
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-00999-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge